Paper41892443
Revisiting the Fight Against Acinetobacter baumannii: Emerging Non-Antibiotic Strategies.
Montini VH and 9 others. Antibiotics (Basel), 2026. Cited by 3 papers, by iCite.
Cite this record
ConductScience Library. Revisiting the Fight Against Acinetobacter baumannii: Emerging Non-Antibiotic Strategies. Papers, record 41892443. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41892443
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Revisiting the Fight Against Acinetobacter baumannii: Emerging Non-Antibiotic Strategies.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| 01.22.0200-00 | FINEP - Materiais Avançados (161/21) | PubMed |
Source PubMed
References103
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 38719540 | Lactate metabolism promotes in vivo fitness during Acinetobacter baumannii infection. | FEMS Microbiol Lett | 2024 | https://conductscience.org/library/papers/38719540 | PubMed |
| 2 | 38797178 | Expanding antibiotic, vaccine, and diagnostics development and access to tackle antimicrobial resistance. | Lancet | 2024 | https://conductscience.org/library/papers/38797178 | PubMed |
| 3 | 33969154 | Neutralizing antibody response against subcutaneously injected bacteriophages in rabbit model. | Virusdisease | 2021 | https://conductscience.org/library/papers/33969154 | PubMed |
| 4 | 39061334 | The Many Lives of Auranofin: How an Old Anti-Rheumatic Agent May Become a Promising Antimicrobial Drug. | Antibiotics (Basel) | 2024 | https://conductscience.org/library/papers/39061334 | PubMed |
| 5 | 35402883 | A Phage Foundry Framework to Systematically Develop Viral Countermeasures to Combat Antibiotic-Resistant Bacterial Pathogens. | iScience | 2022 | https://conductscience.org/library/papers/35402883 | PubMed |
| 6 | 38743467 | Resistance to bacteriophage incurs a cost to virulence in drug-resistant Acinetobacter baumannii. | J Med Microbiol | 2024 | https://conductscience.org/library/papers/38743467 | PubMed |
| 7 | 39421030 | In silico approaches supporting drug repurposing for Leishmaniasis: a scoping review. | EXCLI J | 2024 | https://conductscience.org/library/papers/39421030 | PubMed |
| 8 | 37113664 | A fresh pH-responsive imipenem-loaded nanocarrier against Acinetobacter baumannii with a synergetic effect. | Front Bioeng Biotechnol | 2023 | https://conductscience.org/library/papers/37113664 | PubMed |
| 9 | 40582411 | Isolation and identification of a newly discovered broad-spectrum Acinetobacter baumannii phage and therapeutic validation against pan-resistant Acinetobacter baumannii. | Virol Sin | 2025 | https://conductscience.org/library/papers/40582411 | PubMed |
| 10 | 38517956 | Supercharged precision killers: Genetically engineered biomimetic drugs of screened metalloantibiotics against Acinetobacter baumanni. | Sci Adv | 2024 | https://conductscience.org/library/papers/38517956 | PubMed |
| 11 | 36340146 | Drug-Repurposing Approach To Combat Staphylococcus aureus: Biomolecular and Binding Interaction Study. | ACS Omega | 2022 | https://conductscience.org/library/papers/36340146 | PubMed |
| 12 | 37855599 | Acinetobacter baumannii coordinates central metabolism, plasmid dissemination, and virulence by sensing nutrient availability. | mBio | 2023 | https://conductscience.org/library/papers/37855599 | PubMed |
| 13 | 33718279 | Clinical Experience of Personalized Phage Therapy Against Carbapenem-Resistant Acinetobacter baumannii Lung Infection in a Patient With Chronic Obstructive Pulmonary Disease. | Front Cell Infect Microbiol | 2021 | https://conductscience.org/library/papers/33718279 | PubMed |
| 14 | 35378227 | Repurposing Non-Antibiotic Drugs Auranofin and Pentamidine in Combination to Combat Multidrug-Resistant Gram-Negative Bacteria. | Int J Antimicrob Agents | 2022 | https://conductscience.org/library/papers/35378227 | PubMed |
| 15 | 23892192 | Nanotechnology as a therapeutic tool to combat microbial resistance. | Adv Drug Deliv Rev | 2013 | https://conductscience.org/library/papers/23892192 | PubMed |
| 16 | 41367424 | Identification of multi-drug resistant Acinetobacter baumannii phage YZ2 and evaluation of its therapeutic efficacy in vivo and in vitro. | Front Microbiol | 2025 | https://conductscience.org/library/papers/41367424 | PubMed |
| 17 | 34031472 | Antibiofilm and antivirulence potential of silver nanoparticles against multidrug-resistant Acinetobacter baumannii. | Sci Rep | 2021 | https://conductscience.org/library/papers/34031472 | PubMed |
| 18 | 40341530 | Penfluridol synergizes with colistin to reverse colistin resistance in Gram-negative bacilli. | Sci Rep | 2025 | https://conductscience.org/library/papers/40341530 | PubMed |
| 19 | 39415253 | Antibacterial and wound healing potential of biosynthesized zinc oxide nanoparticles against carbapenem-resistant Acinetobacter baumannii: an in vitro and in vivo study. | Microb Cell Fact | 2024 | https://conductscience.org/library/papers/39415253 | PubMed |
| 20 | 37268109 | The effect of phage-antibiotic combination strategy on multidrug-resistant Acinetobacter baumannii biofilms. | J Microbiol Methods | 2023 | https://conductscience.org/library/papers/37268109 | PubMed |
Cited by3
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 3 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42756188 | Pre-treatment serum extracellular vesicle-enriched microbiome profiles and SSRI treatment response in obsessive-compulsive disorder: a prospective naturalistic cohort study. | Front Psychiatry | 2026 | https://conductscience.org/library/papers/42756188 | PubMed |
| 42423746 | Silver-based N-heterocyclic carbene (NHC) complexes as emerging strategies against antimicrobial resistance. | Arch Microbiol | 2026 | https://conductscience.org/library/papers/42423746 | PubMed |
| 42357332 | Phenotype-Guided Nanotherapeutic Strategies for Carbapenem-Resistant Acinetobacter baumannii: Toward Precision Antimicrobial Intervention. | Pharmaceutics | 2026 | https://conductscience.org/library/papers/42357332 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41892443
GET https://conductscience.org/api/papers/v1/41892443/references?page=2